ACE Exome™ for Cancer Research

Now with enhanced coverage of over 1,300 cancer-related genes

Improving Cancer Sequencing with the ACE Platform™

Personalis provides a wide range of sequencing capabilities that are significantly enhanced with our proprietary ACE technology. ACE provides targeted sequencing to augment coverage gaps present in typical panels and exomes, including enhanced coverage for over 1,300 cancer genes. Improved coverage with ACE translates into increased sensitivity to detect known and novel cancer-associated variation as part of a discovery study, and improved resolution in studies of tumor stratification, metastatic evolution and therapeutic response.

Augment coverage gaps present in typical panels and exomes
Standard Coverage vs. Exome Coverage
FIGURE 1:
Example exon coverage for cancer genes using the ACE Exome vs. standard exome sequencing
Increased sensitivity to detect cancer-associated variation

Finishing Analysis of 1,258 Cancer Genes by Assay

We investigated completeness of coverage over a list of 1,258 cancer genes (including the Cancer Gene Census list) by comparing the current ACE Exome with current standard exome offerings from three major commercial vendors, each run to a total of 16 Gigabases (Gb) of sequencing. ACE Exome covered greater than 99% of bases at greater than 25X mean depth for 1,048 (83%) genes. Standard exomes only covered 840 (67%), 763 (61%), and 676 (54%) respectively.

Finishing Analysis of 1,258 Cancer Genes
FIGURE 2: Overall performance of ACE Exome vs. standard exomes at 16Gb sequencing on over 1,200 cancer genes.

Whole Transcriptome for Cancer Research

Transcriptome sequencing can provide complementarity information to your cancer studies, including data on gene expression levels, fusion transcripts, variants in expressed genes and allelic expression. RNA can be extracted from the same tissue sample used for exome sequencing, maximizing the data generated from limited samples.